|
KMID : 1001020090070030109
|
|
Journal of Urologic Oncology
2009 Volume.7 No. 3 p.109 ~ p.112
|
|
|
Current Role of Immunotherapy for Advanced Renal Cell Carcinoma in the Era of Targeted Therapy
|
|
Kim Hyeong-Gon
|
|
|
Abstract
|
|
|
|
Advanced renal cell carcinoma (RCC) is difficult to treat and is generally resistant to cytotoxic chemotherapy. Only immunotherapy have been accepted as effective tool for minority of patients with advanced RCC. Recently, New targeted agents have shown an impressive activity in advanced RCC with a high response rate and significant improvement of survival. Now targeted agents have become the standard of care for most patients. Nevertheless, immunotherapy especially interleukin-2 (IL-2) remains another important therapeutic tool for advanced RCC. The value of immunotherapy is its curative potential in some patients and its capability to obtain very durable responses. Targeted agents may deprive some patients of a chance for long-term survival in some aspects. The identification of a panel of prognostic factors could provide an important tool to guide the choice of treatment of patients with a different risk profile. The immunotherapy will continue to be an important treatment modality in selected patients with advanced RCC.
|
|
|
KEYWORD
|
|
|
Advanced renal cell carcinoma, Immunotherapy, Interleukin-2
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|